Tata Capital Healthcare Fund II invests $20M in Orbicular Pharmaceutical Technologies for specialty generics market growth.

Tata Capital Healthcare Fund II invested $20M in Hyderabad-based specialty pharma company, Orbicular Pharmaceutical Technologies, to accelerate development of its product pipeline in the specialty generics market. The investment, Orbicular's eighth from TCHF II, is aimed at supporting the company's growth story and aligns with TCHF II's philosophy of being a "capital plus" partner.